Innovent Biologics’s TYVYT/Byvasda combo shows survival benefit in late-stage liver cancer study

Article from Seeking Alpha curated by Contributing Editor George Lundberg, MD, who notes: 

In a phase 3 clinical trial, a new drug combination improved both overall survival and progression-free survival for people with hepatocellular carcinoma.

.